Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034Martin J. van den Bent, Thierry Gorlia, Alba A. Brandes et al.|Journal of Clinical Oncology|2009Cited by 573
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade GliomaMichael Brada, Siow Ming Lee, Sarah Beall et al.|Journal of Clinical Oncology|2010Cited by 248
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group StudyÉric Raymond, Martin J. van den Bent, Alba A. Brandes et al.|Journal of Clinical Oncology|2008Cited by 226
Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034Martin J. van den Bent, Denis Lacombe, A.A. Brandes et al.|Journal of Clinical Oncology|2007Cited by 53
2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034)Martin J. van den Bent, T. Gorlia, R. Rampling et al.|European Journal of Cancer Supplements|2007Cited by 5